Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Hangzhou Tigermed Consulting expects weaker EPS for quarter ended 30 June 2026
Hangzhou Tigermed Consulting is expected to publish quarterly results for the period ended 30 June 2026 on 29 August 2026. Three analysts estimate average EPS of 0.185 CNY per share versus 0.260 CNY in the year-ago quarter. Two analysts expect revenue to increase 12.09 percent to 1.89 billion CNY (prior year: 1.69 billion CNY). For the current fiscal year, analysts’ estimates average 1.02 CNY EPS and 7.75 billion CNY revenue versus 1.04 CNY and 6.81 billion CNY in the prior year. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 274.41m | 29.82% |
| Gross profit | 74.19m | 27.78% |
| Net profit | 18.58m | 75.50% |
| EBITDA | 94.51m | 0.10% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.22bn |
Number of shares | 1.54bn |
52-week high/low | €4.04 - €3.63 |
Dividend yield | 0.13% |
Dividends TTM | €0.0159 |
Beta | 0.41 |
P/E ratio | -99.75 |
PEG ratio | 0.59 |
P/B ratio | 2.03 |
P/S ratio | 4.61 |
Company profile
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
| Name | Hangzhou Tigermed Consulting Co Ltd ADR |
| CEO | Xiao Chun Cao |
| Headquarters | Hangzhou,
tj China |
| Website | |
| IPO | 11/07/2022 |
| Employees | 11,130 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | HNGZY |